Aziyo Biologics price target raised to $10.50 from $9 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Aziyo Biologics to $10.50 from $9 and keeps an Overweight rating on the shares. The company’s Q3 results topped expectations and its management boosted its FY22 guidance, as Aziyo saw 18% growth in its core SimpliDerm and CanGaroo franchises with more strong performance here going forward, the analyst tells investors in a research note. O’Brien adds that he continues to see substantial value in this "unique medtech asset", recommending that investors add to positions at current multiples.